<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906150</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-Ta1-NSCLC-CHEMO P2-001</org_study_id>
    <nct_id>NCT02906150</nct_id>
  </id_info>
  <brief_title>Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type</brief_title>
  <official_title>Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) Chemotherapy Plus Cisplatin (or Carboplatin) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SciClone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SciClone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus&#xD;
      cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC),&#xD;
      EGFR wild type&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression free survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Thymalfasin (Thymosin alpha 1, Ta1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoC (chemotherapy and platinum agent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymalfasin (Thymosin alpha 1, Ta1)</intervention_name>
    <description>Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.</description>
    <arm_group_label>Thymalfasin (Thymosin alpha 1, Ta1)</arm_group_label>
    <other_name>ZADAXIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SoC (chemotherapy and platinum agent)</intervention_name>
    <description>Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.</description>
    <arm_group_label>SoC (chemotherapy and platinum agent)</arm_group_label>
    <arm_group_label>Thymalfasin (Thymosin alpha 1, Ta1)</arm_group_label>
    <other_name>Pemetrexed, carboplatin or cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Histological or cytological confirmation of NSCLC (may be from initial diagnosis of&#xD;
             NSCLC or subsequent biopsy). Only patients with available tissue samples may be&#xD;
             included in the study (see major details in section 8 for the minimum sample&#xD;
             characteristics)&#xD;
&#xD;
          -  Activating mutations of EGFR diagnosis of Stage IIIB (with cytologically proven&#xD;
             pleural effusion or pericardial effusion) or metastatic NSCLC, not amenable to&#xD;
             curative surgery or radiotherapy&#xD;
&#xD;
          -  Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) in a&#xD;
             lesion not previously irradiated or non-measurable disease (non measurable disease&#xD;
             only for Phase I)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group - performance status (ECOG-PS) 0-2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1.5 x 109/liter (L) and platelets &gt; 100 x 109/L&#xD;
&#xD;
          -  Bilirubin level either normal or &lt;1.5 x ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) &lt;2.5 x ULN (â‰¤ 5 x ULN if liver metastases are present)&#xD;
&#xD;
          -  Serum creatinine &lt;1.5 x ULN&#xD;
&#xD;
          -  Effective contraception for both, male and female patients, if the risk of conception&#xD;
             exists&#xD;
&#xD;
          -  Provision of written informed consent to the analysis of biological markers&#xD;
             (registration)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with Thymosin alpha-1&#xD;
&#xD;
          -  Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant&#xD;
             chemotherapy is permitted if at least 12 months has elapsed between the end of&#xD;
             chemotherapy and randomisation&#xD;
&#xD;
          -  Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or&#xD;
             antibodies&#xD;
&#xD;
          -  Radiotherapy within 14 days prior to drug administration, except as follows:&#xD;
&#xD;
          -  Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to&#xD;
             drug administration, and&#xD;
&#xD;
          -  Single dose palliative treatment for symptomatic metastasis outside above allowance to&#xD;
             be discussed with sponsor prior to enrolling&#xD;
&#xD;
          -  Patients with previously diagnosed and treated CNS metastases or spinal cord&#xD;
             compression may be considered if they have evidence of clinically stable disease (SD)&#xD;
             (no steroid therapy or steroid dose being tapered) for at least 28 days&#xD;
&#xD;
          -  Patients with toxicities that have not come back (at least) to grade 1&#xD;
&#xD;
          -  Pregnancy or suspected pregnancy&#xD;
&#xD;
          -  Known severe hypersensitivity to TKI products&#xD;
&#xD;
          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ&#xD;
&#xD;
          -  Any evidence of clinically active interstitial lung disease (ILD) (patients with&#xD;
             chronic, stable, radiographic changes who are asymptomatic or patients with&#xD;
             uncomplicated progressive lymphangitic carcinomatosis need not be excluded)&#xD;
&#xD;
          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease&#xD;
             (e.g., unstable or uncompensated respiratory, cardiac, hepatic or renal disease)&#xD;
&#xD;
          -  As judged by the investigator, any inflammatory changes of the surface of the eye&#xD;
&#xD;
          -  Evidence of any other significant clinical disorder or laboratory finding that makes&#xD;
             it undesirable for the patient to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlo Tomino, MD</last_name>
    <email>carlotomino@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Frosinone</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Dott.ssa Teresa Gamucci</last_name>
    </contact>
    <investigator>
      <last_name>Dott.ssa Teresa Gamucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Dott.ssa Marina Chiara Garassino</last_name>
    </contact>
    <investigator>
      <last_name>Dott.ssa Marina Chiara Garassino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roma_Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof. Daniele Santini</last_name>
    </contact>
    <investigator>
      <last_name>Prof. Daniele Santini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roma_Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof. Carlo Antonio Mario Barone</last_name>
    </contact>
    <investigator>
      <last_name>Prof. Carlo Antonio Mario Barone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roma_Regina Apostolorum</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Dott. Francesco Angelini</last_name>
    </contact>
    <investigator>
      <last_name>Dott. Francesco Angelini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roma_Tor Vergata</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof. Mario Roselli</last_name>
    </contact>
    <investigator>
      <last_name>Prof. Mario Roselli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sant'Andrea Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof. Paolo Marchetti</last_name>
    </contact>
    <investigator>
      <last_name>Prof. Paolo Marchetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Sanitario San Camillo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Dott.ssa Maria Rita Migliorino</last_name>
    </contact>
    <investigator>
      <last_name>Dott.ssa Maria Rita Migliorino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR Wild Type</keyword>
  <keyword>Thymosin Alpha 1</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Thymalfasin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

